Suven Pharmaceuticals rose 2.52% to Rs 765.75 after the company said its board fixed 28 September 2020 as the record date to ascertain shareholders eligible to receive bonus shares.
Last month, the board of Suven Pharma recommended issuing one bonus share for each share held (1:1).
The stock surged 339.83% from its 52-week low of Rs 174.10 hit on 24 March 2020.
The pharma company's consolidated net profit fell 0.4% to Rs 91.52 crore on a 20.7% increase in net sales to Rs 238.23 crore in Q1 June 2020 over Q1 June 2019.
Suven Pharmaceuticals is engaged in the business of contract development and manufacturing operations (CDMO).
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.